Benitec Biopharma grants 666,558 stock options to CEO and executive director at $5.21

Benitec Biopharma Inc.

Compensation Committee approved nonqualified options for CEO Jerel Banks (466,554 shares) and Exec. Director Megan Boston (200,004 shares).
Exercise price of $5.21 per share equals March 6, 2024 closing price.
Options vest in three equal annual installments; full acceleration upon change in control.
Grants made under the Company's 2020 Equity and Incentive Compensation Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.